Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.

Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono J.

Clin Cancer Res. 2019 Aug 1;25(15):4624-4633. doi: 10.1158/1078-0432.CCR-18-3212. Epub 2019 May 21.


Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.


A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.

Thakar M, Hu Y, Morreale M, Lerner L, Ying Lin W, Sen R, Cai Y, Karunasena E, Thakar M, Saggi S, Keer H, Ahuja N.

PLoS One. 2018 Jun 21;13(6):e0199130. doi: 10.1371/journal.pone.0199130. eCollection 2018.


Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.

Tang J, Pulliam N, Özeş A, Buechlein A, Ding N, Keer H, Rusch D, O'Hagan H, Stack MS, Nephew KP.

Mol Cancer Res. 2018 Aug;16(8):1226-1240. doi: 10.1158/1541-7786.MCR-17-0406. Epub 2018 May 14.


Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma.

De Carvalho Fischer C, Hu Y, Morreale M, Lin WY, Wali A, Thakar M, Karunasena E, Sen R, Cai Y, Murphy L, Zahnow CA, Keer H, Thakar M, Ahuja N.

Oncotarget. 2018 Apr 10;9(27):19379-19395. doi: 10.18632/oncotarget.25056. eCollection 2018 Apr 10.


An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.


A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF.

Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.


Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D.

Cancer Res. 2018 Feb 1;78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. Epub 2017 Dec 11.


Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.


A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.


Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Rabe DC, Cecchi F, Bottaro DP, LoRusso P.

Invest New Drugs. 2015 Dec;33(6):1292. doi: 10.1007/s10637-015-0287-6. No abstract available.


Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14.


A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Lorusso P.

Invest New Drugs. 2013 Jun;31(3):742-50. doi: 10.1007/s10637-012-9881-z. Epub 2012 Oct 6. Erratum in: Invest New Drugs. 2015 Dec;33(6):1292.


Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr.

Invest New Drugs. 2013 Apr;31(2):417-24. doi: 10.1007/s10637-012-9861-3. Epub 2012 Aug 24.


Students' objectively measured physical activity levels and engagement as a function of between-class and between-student differences in motivation toward physical education.

Aelterman N, Vansteenkiste M, Van Keer H, Van den Berghe L, De Meyer J, Haerens L.

J Sport Exerc Psychol. 2012 Aug;34(4):457-80.


In silico predictions of LH2 ring sizes from the crystal structure of a single subunit using molecular dynamics simulations.

Janosi L, Keer H, Cogdell RJ, Ritz T, Kosztin I.

Proteins. 2011 Jul;79(7):2306-15. doi: 10.1002/prot.23056. Epub 2011 May 20.


A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM.

Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.


Using steered molecular dynamics simulations and single-molecule force spectroscopy to guide the rational design of biomimetic modular polymeric materials.

Guzmán DL, Roland JT, Keer H, Kong YP, Ritz T, Yee A, Guan Z.

Polymer (Guildf). 2008 Sep 26;49(18):3892-3901.


Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.

Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A.

Lung Cancer. 2004 Sep;45(3):381-6.


Computing fuzzy associations for the analysis of biological literature.

Perez-Iratxeta C, Keer HS, Bork P, Andrade MA.

Biotechniques. 2002 Jun;32(6):1380-2, 1384-5.


Disseminated coccidioidomycosis diagnosed by culture of a central venous catheter tip.

Wagner JA, Keer H, Fredricks DN.

Clin Infect Dis. 1996 Jan;22(1):180-1. No abstract available.


Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.

N Engl J Med. 1995 May 25;332(21):1393-8.


DNA profile of nephrogenic adenoma assessed by flow cytometry.

Gaylis FD, Keer HN, Bauer KD, Kozlowski JM, Grayhack JT.

Urology. 1993 Feb;41(2):160-1.


Superconductivity at 86 K in LuBa2Cu3O7- delta thin films.

Pinto R, Pai SP, Tamhane AS, Apte PR, Gupta LC, Vijayaraghavan R, Gnanasekar KI, Keer HV.

Phys Rev B Condens Matter. 1992 Dec 1;46(21):14242-14244. No abstract available.


Components of the plasminogen-plasmin system in human tumor cell lines.

Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R.

Semin Thromb Hemost. 1991 Jul;17(3):175-82. Review. No abstract available.


Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.

Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ.

Prostate. 1991;18(3):201-14.


Fibrinolysis and cancer.

Kwaan HC, Keer HN.

Semin Thromb Hemost. 1990 Jul;16(3):230-5. Review. No abstract available.


Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo.

Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT.

J Urol. 1990 Feb;143(2):381-5.


Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.

Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM.

J Urol. 1989 Jul;142(1):193-8.


Effect of localized hyperthermia on TA3Ha tumor transplanted subcutaneously in the tails of mice.

Murthy MS, Keer HN, Travis JD, Cohen JD, Mollick JA, Khandekar JD, Scanlon EF.

Cancer Res. 1984 Sep;44(9):3836-40.

Supplemental Content

Support Center